First-in-Human Clinical Trial of EpiEndo’s Lead Compound, EP395, for Chronic Inflammatory Airway Diseases Commences at the Medicines Evaluation Unit in Manchester, UK.

EpiEndo Pharmaceuticals is pleased to announce the appointment of Dr. Sigríður Valgeirsdóttir and Robert Helgason to the Company’s Board of Directors.

EpiEndo Pharmaceuticals is pleased to announce that their consortium project EPIcoliX has been officially recognized as a Eurostar labelled project.

EpiEndo Pharmaceuticals is pleased to announce the appointment of Professor Dr Michael Parnham, PhD, CBiol, MRSB, FBPhS as Chief Scientific Officer (CSO) and Dr Ginny Norris, MRCP, FFPM, DCPSA, in the role of Chief Medical Officer (CMO).

The Board of EpiEndo Pharmaceuticals is pleased to announce the appointment of Maria Bech, MSc as Chief Executive Officer (CEO) of the Company, effective immediately.

EpiEndo Pharmaceuticals announced today that the Company has received approval of its Clinical Trial Application (CTA) from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to commence phase 1 clinical trials of EP395, the Company's lead compound.

EpiEndo Pharmaceuticals is pleased to share important findings in a poster at the ERS (European Respiratory Society) International Congress this year.

EpiEndo’s CEO, Fredrik Lehmann and Finnur Fridrik Einarsson (COO) will represent EpiEndo at the LSX World Congress in London from the 4-5th February 2020.

EpiEndo is very proud to be among 75 promising start-ups and SMEs to be selected by the European Innovation Council (EIC) to receive a grant of € 2.5 million, and one of 39 to go into discussions with the EIC for a direct equity investment of € 2.7 million.